Vor Bio, a clinical-stage biotechnology firm focused on transforming the treatment landscape for autoimmune diseases, has announced the appointment of Jeremy Sokolove, M.D., as its new Chief Medical Officer. This decision, made public on November 3, 2025, brings Dr. Sokolove”s extensive clinical and translational expertise to the leadership team of the company.
“We are thrilled to welcome Jeremy to Vor Bio,” stated Jean-Paul Kress, M.D., the Chief Executive Officer and Chairman of the Board. “His profound clinical knowledge as a rheumatologist, combined with his proven record in the industry and as a thought leader in research related to autoimmune and inflammatory diseases, makes him an ideal candidate to guide our clinical strategy. With Jeremy joining our team, we feel more confident than ever in advancing our dual BAFF/APRIL approach to create a significant impact for patients.”
Prior to this role, Dr. Sokolove was the Chief Medical Officer In-Residence at Roivant Sciences, where he led the strategic evaluation and in-licensing of innovative therapeutic opportunities. He offered operational leadership, clinical advice, and translational expertise across Roivant”s various portfolio companies. Before his time at Roivant, he held the position of Chief Medical Officer at Odyssey Therapeutics, overseeing the company”s transition to a clinical-stage organization dedicated to developing next-generation immunomodulators for autoimmune and inflammatory diseases.
Dr. Sokolove previously served as Senior Vice President and Head of Clinical Pharmacology and Experimental Medicine at GSK, where he directed early and translational development for the specialty pharmaceutical portfolio. Additionally, he was the Head of Immunology Translational Science at AbbVie, managing early-phase clinical programs and shaping the overall translational medicine strategy for the portfolio.
He began his career on the faculty at Stanford University School of Medicine as a practicing rheumatologist and principal investigator, focusing his research on biomarker discovery and immune-mediated disease mechanisms. Dr. Sokolove has a robust clinical background, having treated numerous patients and led clinical research initiatives targeting autoimmune and inflammatory disorders. His contributions to the fields of immunology and rheumatology are extensive, with numerous publications advancing the understanding of immune-mediated disease mechanisms. He is board-certified in internal medicine and rheumatology and earned his MD from the Boston University School of Medicine.
“I am joining Vor Bio because I see substantial scientific and clinical potential in the BAFF/APRIL pathways to accurately modulate the underlying mechanisms of autoimmune diseases,” remarked Dr. Sokolove. “Telitacicept stands out as a unique, near-term opportunity to significantly enhance outcomes for patients who have limited treatment options or who are reliant on broad immunosuppression. I am eager to collaborate with the team to implement a global clinical development program for Telitacicept that could lead to a therapy making a tangible difference in patients” lives.”
Vor Bio is committed to rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development with an eye toward potential commercialization for addressing serious autoantibody-driven conditions on a global scale. For further information, visit www.vorbio.com.
This press release also contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, with various expressions indicating potential future outcomes. However, actual results may differ due to numerous factors, including the data for product candidates that may not meet regulatory approval for commercialization.
For media and investor inquiries, please contact:
- Carl Mauch: [email protected]
- Sarah Spencer: [email protected]
